These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32400907)

  • 21. Extended-release tacrolimus dosing and outcomes in pediatric and young adult transplant recipients - A single-center experience.
    Huang X; Hapgood K; Allan K; Pruette C; Goswami E
    Pediatr Transplant; 2024 Feb; 28(1):e14611. PubMed ID: 37735900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism.
    Schulte K; Vollmer C; Klasen V; Bräsen JH; Püchel J; Borzikowsky C; Kunzendorf U; Feldkamp T
    J Nephrol; 2017 Aug; 30(4):607-615. PubMed ID: 28540602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis.
    Stratta RJ; Alloway RR; Hodge E; Lo A;
    Clin Transplant; 2002 Feb; 16(1):60-8. PubMed ID: 11982617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beta Cell Function and Insulin Resistance After Conversion from Tacrolimus Twice-Daily to Extended-Release Tacrolimus Once-Daily in Stable Renal Transplant Recipients.
    Ruangkanchanasetr P; Sanohdontree N; Supaporn T; Sathavarodom N; Satirapoj B
    Ann Transplant; 2016 Dec; 21():765-774. PubMed ID: 27980321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conversion from tacrolimus to belatacept to prevent the progression of chronic kidney disease in pancreas transplantation: case report of two patients.
    Mujtaba MA; Sharfuddin AA; Taber T; Chen J; Phillips CL; Goble M; Fridell JA
    Am J Transplant; 2014 Nov; 14(11):2657-61. PubMed ID: 25179306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of tacrolimus and cyclosporin A in CYP3A5 expressing Chinese de novo kidney transplant recipients: a 2-year prospective study.
    Liu LS; Li J; Chen XT; Zhang HX; Fu Q; Wang HY; Xiong YY; Liu S; Liu XM; Li JL; Huang M; Wang CX
    Int J Clin Pract Suppl; 2015 May; (183):43-52. PubMed ID: 26177348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinct peripheral blood molecular signature emerges with successful tacrolimus withdrawal in kidney transplant recipients.
    Cravedi P; Fribourg M; Zhang W; Yi Z; Zaslavsky E; Nudelman G; Anderson L; Hartzell S; Brouard S; Heeger PS
    Am J Transplant; 2020 Dec; 20(12):3477-3485. PubMed ID: 32459070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advagraf® with or without an induction therapy for de novo kidney-transplant recipients.
    Noble J; Jouve T; Rostaing L; Malvezzi P
    Expert Rev Clin Immunol; 2018 Jun; 14(6):461-467. PubMed ID: 29757021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of LCP-Tacrolimus (Envarsus XR) in simultaneous pancreas and kidney (SPK) transplant recipients.
    Torabi J; Konicki A; Rocca JP; Ajaimy M; Campbell A; Azzi Y; Pynadath C; Liriano-Ward L; Akalin E; Kinkhabwala M; Graham JA
    Am J Surg; 2020 Apr; 219(4):583-586. PubMed ID: 32122660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate- or prolonged-release tacrolimus.
    Vondrak K; Parisi F; Dhawan A; Grenda R; Webb NJA; Marks SD; Debray D; Holt RCL; Lachaux A; Kelly D; Kazeem G; Undre N
    Clin Transplant; 2019 Oct; 33(10):e13698. PubMed ID: 31436896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A switch from conventional twice-daily tacrolimus to once-daily extended-release tacrolimus in stable kidney transplant recipients.
    Hatakeyama S; Fujita T; Yoneyama T; Yoneyama T; Koie T; Hashimoto Y; Saitoh H; Funyu T; Narumi S; Ohyama C
    Transplant Proc; 2012 Jan; 44(1):121-3. PubMed ID: 22310594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras.
    Nankivell BJ; PʼNg CH; OʼConnell PJ; Chapman JR
    Transplantation; 2016 Aug; 100(8):1723-31. PubMed ID: 27306529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimal blood levels of (extended-release) tacrolimus in living donor kidney transplantation to prevent de novo donor-specific antibody production: A retrospective cohort study.
    Hiramitsu T; Tomosugi T; Futamura K; Okada M; Nishihira M; Goto N; Ichimori T; Narumi S; Kobayashi T; Uchida K; Watarai Y
    Int Immunopharmacol; 2021 Feb; 91():107038. PubMed ID: 33388731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
    Guethoff S; Stroeh K; Grinninger C; Koenig MA; Kleinert EC; Rieger A; Mayr T; von Ziegler F; Reichart B; Hagl C; Schramm R; Kaczmarek I; Meiser BM
    J Heart Lung Transplant; 2015 May; 34(5):634-42. PubMed ID: 25701373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pilot Randomized Trial of Tacrolimus/Everolimus vs Tacrolimus/Enteric-Coated Mycophenolate Sodium in Adult, Primary Kidney Transplant Recipients at a Single Center.
    Ciancio G; Tryphonopoulos P; Gaynor JJ; Guerra G; Sageshima J; Roth D; Chen L; Kupin W; Mattiazzi A; Tueros L; Flores S; Hanson L; Powell RH; Ruiz P; Vianna R; Burke GW
    Transplant Proc; 2016; 48(6):2006-10. PubMed ID: 27569936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
    Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
    Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology.
    Stevens RB; Foster KW; Miles CD; Kalil AC; Florescu DF; Sandoz JP; Rigley TH; Malik T; Wrenshall LE
    PLoS One; 2015; 10(10):e0139247. PubMed ID: 26465152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. No Significant Influence of Reduced Initial Tacrolimus Dose on Risk of Underdosing and Early Graft Function in Older and Overweight Kidney Transplant Recipients.
    Krzyżowska K; Kolonko A; Giza P; Chudek J; Więcek A
    Transplant Proc; 2018; 50(6):1755-1759. PubMed ID: 30056895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prolonged-Release Once-Daily Formulation of Tacrolimus Versus Standard-of-Care Tacrolimus in
    Budde K; Rostaing L; Maggiore U; Piotti G; Surace D; Geraci S; Procaccianti C; Nicolini G; Witzke O; Kamar N; Albano L; Büchler M; Pascual J; Gutiérrez-Dalmau A; Kuypers D; Wekerle T; Głyda M; Carmellini M; Tisone G; Midtvedt K; Wennberg L; Grinyó JM
    Transpl Int; 2022; 35():10225. PubMed ID: 36017158
    [No Abstract]   [Full Text] [Related]  

  • 40. Safety and Effectiveness of Once-Daily, Prolonged-Release Tacrolimus in De Novo Kidney Transplant Recipients: 5-year, Multicenter Postmarketing Surveillance in Japan.
    Wakasugi N; Uchida H; Uno S
    Transplant Proc; 2018 Dec; 50(10):3296-3305. PubMed ID: 30577199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.